Preclinical Metabolism, Pharmacokinetics and In Vivo Analysis of New Blood-Brain-Barrier Penetrant Fingolimod Analogues: FTY720-C2 and FTY720-Mitoxy

Active, phosphorylated fingolimod inhibits histone deacetylases and facilitates fear extinction memory

(2014) Nitai C Hait et al.   NATURE NEUROSCIENCE

A novel α-synuclein mutation A53E associated with atypical multiple system atrophy and Parkinson's disease-type pathology

(2014) Petra Pasanen et al.   NEUROBIOLOGY OF AGING

Novel FTY720-Based Compounds Stimulate Neurotrophin Expression and Phosphatase Activity in Dopaminergic Cells

(2014) Javier Vargas-Medrano et al.   ACS Medicinal Chemistry Letters

G51D α-synuclein mutation causes a novel Parkinsonian-pyramidal syndrome

(2013) Suzanne Lesage et al.   ANNALS OF NEUROLOGY

Antagonistic activities of the immunomodulator and PP2A-activating drug FTY720 (Fingolimod, Gilenya) in Jak2-driven hematologic malignancies

(2013) J. J. Oaks et al.   BLOOD

FTY720 (fingolimod) is a neuroprotective and disease-modifying agent in cellular and mouse models of Huntington disease

(2013) Alba Di Pardo et al.   HUMAN MOLECULAR GENETICS

Non-motor parkinsonian pathology in aging A53T α-Synuclein mice is associated with progressive synucleinopathy and altered enzymatic function

(2013) Kaitlin F. Farrell et al.   JOURNAL OF NEUROCHEMISTRY

Fingolimod phosphate promotes the neuroprotective effects of microglia

(2013) Hiromi Noda et al.   JOURNAL OF NEUROIMMUNOLOGY

The mitochondrial permeability transition pore regulates Parkinson's disease development in mutant α-synuclein transgenic mice

(2013) Lee J. Martin et al.   NEUROBIOLOGY OF AGING

Fingolimod Phosphate Attenuates Oligomeric Amyloid β–Induced Neurotoxicity via Increased Brain-Derived Neurotrophic Factor Expression in Neurons

(2013) Yukiko Doi et al.   PLoS One

Lewy-like aggregation of α-synuclein reduces protein phosphatase 2A activity in vitro and in vivo

(2012) J. Wu et al.   NEUROSCIENCE

Fingolimod (FTY720) inhibits neuroinflammation and attenuates spontaneous convulsions in lithium-pilocarpine induced status epilepticus in rat model

(2012) Fei Gao et al.   PHARMACOLOGY BIOCHEMISTRY AND BEHAVIOR

Fingolimod, a sphingosine-1 phosphate receptor modulator, increases BDNF levels and improves symptoms of a mouse model of Rett syndrome

(2012) R. Deogracias et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Fingolimod provides long-term protection in rodent models of cerebral ischemia

(2010) Ying Wei et al.   ANNALS OF NEUROLOGY

Absorption and Disposition of the Sphingosine 1-Phosphate Receptor Modulator Fingolimod (FTY720) in Healthy Volunteers: A Case of Xenobiotic Biotransformation Following Endogenous Metabolic Pathways

(2010) M. Zollinger et al.   DRUG METABOLISM AND DISPOSITION

CYP4F Enzymes Are Responsible for the Elimination of Fingolimod (FTY720), a Novel Treatment of Relapsing Multiple Sclerosis

(2010) Y. Jin et al.   DRUG METABOLISM AND DISPOSITION

Serine 129 Phosphorylation Reduces the Ability of α-Synuclein to Regulate Tyrosine Hydroxylase and Protein Phosphatase 2Ain Vitroandin Vivo

(2010) Haiyan Lou et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

The Transgenic Overexpression of α-Synuclein and Not Its Related Pathology Associates with Complex I Inhibition

(2010) Virginie Loeb et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Sodium selenate specifically activates PP2A phosphatase, dephosphorylates tau and reverses memory deficits in an Alzheimer’s disease model

(2010) Niall M. Corcoran et al.   JOURNAL OF CLINICAL NEUROSCIENCE

Cell-surface residence of sphingosine 1-phosphate receptor 1 on lymphocytes determines lymphocyte egress kinetics

(2010) Shobha Thangada et al.   JOURNAL OF EXPERIMENTAL MEDICINE

Fingolimod (FTY720): discovery and development of an oral drug to treat multiple sclerosis

(2010) Volker Brinkmann et al.   NATURE REVIEWS DRUG DISCOVERY

Sodium selenate mitigates tau pathology, neurodegeneration, and functional deficits in Alzheimer's disease models

(2010) J. van Eersel et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Alpha-synuclein overexpression and aggregation exacerbates impairment of mitochondrial functions by augmenting oxidative stress in human neuroblastoma cells

(2009) Mordhwaj S. Parihar et al.   INTERNATIONAL JOURNAL OF BIOCHEMISTRY & CELL BIOLOGY

Mitochondrial dysfunction in the limelight of Parkinson's disease pathogenesis

(2008) Rebecca Banerjee et al.   BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR BASIS OF DISEASE

Protein phosphatase 2A (PP2A), a drugable tumor suppressor in Ph1(+) leukemias

(2008) Danilo Perrotti et al.   CANCER AND METASTASIS REVIEWS

α-Synuclein aggregation alters tyrosine hydroxylase phosphorylation and immunoreactivity: Lessons from viral transduction of knockout mice

(2008) Tshianda N.M. Alerte et al.   NEUROSCIENCE LETTERS

Mitochondrial biology and oxidative stress in Parkinson disease pathogenesis

(2008) Claire Henchcliffe et al.   Nature clinical practice. Neurology